Pregabalin: Potential for Addiction and a Possible Glutamatergic Mechanism

Yusuf S. Althobaiti1,2*, Atiah Almalki2,3, Hashem Alsaab2,4, Walaa Alsanie2,5, Ahmed Gaber2,6, Qasim Alhadidi7, Ana Maria Gregio Hardy8, Abdulrahman Nasr1, Omar Alzahrani3, Creed M. Stary7 & Zahoor A. Shah9

Drug addiction remains a prevalent and fatal disease worldwide that carries significant social and economic impacts. Recent reports suggest illicit pregabalin (Lyrica) use may be increasing among youth, however the addictive potential of pregabalin has not been well established. Drug seeking behavior and chronic drug use are associated with deficits in glutamate clearance and activation of postsynaptic glutamatergic receptors. In the current study, we investigated the abuse potential of pregabalin using conditioned place preference (CPP) paradigm. Different doses of pregabalin (30, 60, 90, and 120 mg/kg) were used to assess the seeking behavior in mice. Glutamate homeostasis is maintained by glutamate transporter type-1 (GLT-1), which plays a vital role in clearing the released glutamate from synapses and drug seeking behavior. Therefore, we investigated the role of glutamate in pregabalin-seeking behavior with ceftriaxone (CEF), a potent GLT-1 upregulator. Mice treated with pregabalin 60 and 90 mg/kg doses demonstrated drug seeking-like behavior, which was significantly blocked by CEF pretreatment. These results suggest that pregabalin-induced CPP was successfully modulated by CEF which could serve as a lead compound for developing treatment for pregabalin abuse.

Addiction to several drugs and substances remains a critical health issue worldwide. According to the world drug report, Saudi Arabia had one of the highest reported drug seizure rates in 20111. As stated in several reports, the prevalence of drug addiction is high in Saudi Arabia, as are associated rates of hepatitis, HIV, crime, and socioecononomic decline (for review see2). Illicit Pregabalin (Lyrica) use has recently become more common among young Saudis and worldwide3–10, likely secondary to lack of appropriate regulation. Pregabalin is an analogue of the neurotransmitter gamma-aminobutyric acid (GABA) that can bind with strong affinity to the α2δ subunit of pre-synaptic voltage-gated calcium channel receptor to decrease post-synaptic excitatory neurotransmitter release11. Pregabalin has a therapeutic value in the management of fibromyalgia, generalized anxiety disorder, diabetic neuropathy, partial epilepsy, and postherpetic neuralgia12–14. There remains controversy regarding the abuse potential of pregabalin in preclinical studies. In conditioned place preference (CPP) studies conducted in rats, pregabalin (up to 30 mg/kg) did not cause rewarding effects and did not change place preference15,16. However, these doses were small compared to higher doses used in previous case reports of pregabalin abuse4–9. Interestingly, pregabalin has been reported to cause euphoric effects as a side effect in participants of controlled clinical studies17–20. Importantly, glutamate is the major excitatory neurotransmitter in the brain. The nucleus accumbens (NAc) is involved in the reinforcing and rewarding effects of several drugs of abuse21–23. Disturbances in glutamate homeostasis in the NAc have been shown to be associated with drug seeking behavior and chronic drug use24–28. The

1Taif University, College of Pharmacy, Department of Pharmacology and Toxicology, Taif, Saudi Arabia. 2Taif University, College of Pharmacy, Addiction and Neuroscience Research Unit, Taif, Saudi Arabia. 3Taif University, College of Pharmacy, Department of Pharmaceutical Chemistry, Taif, Saudi Arabia. 4Taif University, College of Pharmacy, Department of Pharmaceutics and Pharmaceutical Technology, Taif, Saudi Arabia. 5Taif University, Faculty of Applied Medical Sciences, Department of Clinical Laboratories Sciences, Taif, Saudi Arabia. 6Taif University, Faculty of Sciences, Department of Biology, Taif, Saudi Arabia. 7Department of Anesthesiology, Perioperative and Pain Medicine, Stanford Medical School, Stanford University, CA, USA. 8Department of Physiology and Pharmacology, College of Medicine and Life Sciences, University of Toledo, OH, USA. 9Department of Medicinal and Biological Chemistry, College of Pharmacy and Pharmaceutical Sciences, University of Toledo, OH, USA. *email: ys.althobaiti@tu.edu.sa
release of glutamate from prefrontal cortex (PFC) projections into the NAc has been shown to mediate drug seeking behavior in previous studies\(^29,30\). Blocking glutamatergic activation of mGlu\(^{31}\), mGlu5\(^{32,33}\), AMPA receptors along with blocking the release of glutamate in the NAc was found to reduce reinstatement of self-administration for different drugs of abuse\(^30,34–36\). It is noteworthy that glutamate homeostasis is controlled by a number of glutamate receptors and transporters. One of these transporters is glutamate transporter type-1 (GLT-1) which can clear the majority of the synaptic glutamate\(^37–40\). Moreover, treatment with ceftriaxone (CEF), a well-known upregulator of GLT-1 expression, has been shown to oppose drug-seeking behavior induced, in part, by downregulation of GLT-1 following exposure to several drugs of abuse\(^26,41–45\). Therefore, in the present study we explored the abuse potential of different doses of pregabalin using CPP and assessed the potential mechanistic role of GLT-1 in pregabalin associated drug-seeking behavior by pretreatment with CEF.

**Materials and Methods**

**Animals.** Male BALB/c mice, weighing 25–30 g were obtained from King Fahd Medical Research Center (KFMRC, Jeddah, SA). Mice were housed in standard cages with controlled constant temperature (21 °C) and humidity (30%) on a 12:12 light-dark cycle. Animals had *ad libitum* intake of water and food. Mice were allowed to habituate for seven days before conducting any experiments. The experimental procedures of animals were ethically approved by the Research Ethics Committee at Taif University, in accordance with the Institutional Animal Care and Use Committee of the National Institutes of Health guide.

**Drugs.** Pregabalin was generously provided by Jamjoom Pharmaceuticals (Jeddah, KSA). Ceftriaxone was gifted by King Abdulaziz Hospital at Taif. All the drugs used in this study were reconstituted in sterile saline solution (0.9% NaCl).

**Experimental design.** The overall experimental design is presented in Fig. 1A.

Experiment 1: Mice were randomly assigned into five groups; Group 1: Control group (n = 8), mice in this group were treated with vehicle for 8 days. Group 2: Preg-30 group (n = 8), mice were injected with pregabalin (30 mg/kg, i.p.x 4) and vehicle for eight days during the acquisition phase. Group 3: Preg-60 group (n = 8), mice were injected with pregabalin (60 mg/kg, i.p.x 4) and vehicle for eight days during the acquisition phase. Group 4: Preg-90 group (n = 8), mice were injected with pregabalin (90 mg/kg, i.p.x 4) and vehicle for eight days during the acquisition phase. Group 5: Preg-120 group (n = 8), mice were injected with pregabalin (120 mg/kg, i.p.x 4) and vehicle for eight days during the acquisition phase. Mice were then examined for place preference following completing the conditioning training.

Experiment 2: Mice were randomly assigned into four groups; Group 1: C-C group (n = 8) Mice in this group were treated with vehicle in home cage as a 30 minutes pretreatment and vehicle for eight days during the acquisition phase. Group 2: CEF-C group (n = 8) Mice were injected with CEF (200 mg/kg, i.p.) in home cage as a 30 minutes pretreatment followed by vehicle (60 mg/kg) or saline as in experiment 1.

![Figure 1.](image-url)
(n = 8) Mice were treated with vehicle in home cage as a 30 minutes pretreatment and then Pregabalin (60 mg/kg, i.p.x4) as well as vehicle for eight days during the acquisition phase. The dose of Pregabalin which induced CPP in the previous experiment was used in this study. Group 4: CEF-Preg group (n = 8) Mice were injected with CEF (200 mg/kg, i.p.) in home cage as a 30 minutes pretreatment and then Pregabalin (60 mg/kg, i.p.x4) as well as vehicle for eight days during the acquisition phase. Mice were then examined for place preference following completing the conditioning training.

Conditioned place preference paradigm. A custom made acrylic CPP apparatus (Fig. 1B) was used in this study as described in our previous work. Briefly, this apparatus consists of two equal-sized conditioning chambers (35 cm x 35 cm x 50 cm), and one start box (10 cm x 15 cm x 10 cm) located outside of the CPP apparatus. The two conditioning chambers are distinguished by both tactile and visual cues. The interior walls of the first chamber are white in color with horizontal black stripes and textured walls (chamber 1). The interior walls of the other chamber (chamber 2) are black in color with vertical white stripes and smooth walls. The floor of chamber 1 is perforated with round holes. The floor of the other chamber is perforated with rectangle holes.

Habituation phase: The preconditioning day is considered as day one. On days one, two, and three each mouse was placed in the start box with door closed for 3 minutes. Then, the door was opened to let the mouse explore the conditioning chambers for 30 minutes. On day three, the animal exploration in both conditioning chambers was recorded by a digital camera fixed on the top of the apparatus. The time spent in both chambers was calculated using ANY-maze software (Stoelting, USA).

Conditioning phase: An un-biased CPP design has been used. Therefore, in each treatment group, half of the animals were randomly assigned to receive pregabalin and were placed in chamber 1, while the other half received this drug and were placed in chamber 2 during the conditioning phase (days four to eleven). Each mouse received intraperitoneal injection of specific treatment and were then located in the corresponding chamber with the door closed for 30 minutes session. On the following day, each mouse received vehicle and was located in the other chamber with the door closed for 30 minutes. The process was repeated until the completion of the eight conditioning sessions.

On day twelve, each mouse had free access to both chambers for 30 minutes. The time spent by the mice in both chambers was documented using digital camera (post-conditioning test) and counted by ANY-maze video tracking system.

Statistical analysis. Two-way repeated measure ANOVA, (Phase x Treatment) was used to analyze time spent, at two different timepoints (pre-test and post-test), in the conditioning chambers in response to the selected dose of pregabalin or saline. This analysis was selected based on previous published work. When significant main interactions or effects were found, Newman-Keuls multiple comparisons were performed. All data were statistically analyzed by GraphPad Prism, using a 0.05 level of significance.

Results

Experiment 1. In this experiment, the abuse potential of different doses of pregabalin was assessed. No significant effect was revealed when mice were treated with saline in the conditioning training in phase [F (1, 7) = 0.1697, p = 0.6927], treatment [F (1, 7) = 0.08970, p = 0.8965], and interaction either over phase and between treatments [F (1, 7) = 0.0006396, p = 0.9805; Fig. 1B]. After treatment with 30 mg/kg pregabalin throughout the conditioning phase, no significant effect was observed over phase [F (1, 7) = 5.282, p = 0.0551], or between treatments [F (1, 7) = 0.02283, p = 0.8842], and interaction between phase and treatment [F (1, 7) = 0.01197, p = 0.9160; Fig. 2A].

No significant effect was observed between mice when treated with 60 mg/kg pregabalin throughout the conditioning training over phase [F (1, 9) = 2.215, p = 0.1709], however, we observed a significant effect between treatments [F (1, 9) = 6.929, p = 0.0273], and an association between phase and treatments [F (1, 9) = 38.02, p = 0.0002]. Post-hoc analysis demonstrated that time spent was significantly elevated in pregabalin-paired chamber in comparison with saline-paired chamber in the post-test (p < 0.0001; Fig. 2B), and time spent was significantly increased in pregabalin-paired chamber in the post-test compared to the pre-test (p < 0.01; Fig. 2B).

No significant effect was observed between mice when treated with 90 mg/kg pregabalin during the conditioning training over phase [F (1, 8) = 1, p = 0.3466], but a significant effect was observed between treatments [F (1, 8) = 7.195, p = 0.0278], and a significant association was observed over phase and between treatments [F (1, 8) = 6.036, p = 0.0395]. Post-hoc analysis revealed time spent in the pregabalin-paired chambers was significantly elevated in comparison to saline-paired chamber in the post-test (p < 0.05; Fig. 3A).

Administration of 120 mg/kg of pregabalin through the conditioning phase showed no significant change over phase [F (1, 10) = 0.8837, p = 0.3693] or between treatments [F (1,10) = 0.04083, p = 0.8439], and there was no considerable association between phase and treatment [F (1, 10) = 0.8968; Fig. 3B].

Experiment 2. In this experiment, the effects of CEF pretreatment on pregabalin (60 mg/kg) was assessed. When mice were treated with saline in home cage followed by saline treatment during the conditioning phase, no significant effect over phase [F (1, 5) = 5, p = 0.0756], between treatments [F (1,5) = 0.02791, p = 0.8739], or interaction between phase and treatment [F (1, 5) = 0.03735, p = 0.8544; Fig. 4A] were observed.

When mice were treated with saline after 30 minutes of treatment with 200 mg/kg CEF, in home cages, no significant effect over phase [F (1, 7) = 1, p = 0.3506], between treatments [F (1,7) = 0.001810, p = 0.8968], or between phase and treatment [F (1, 7) = 0.7249, p = 0.4227; Fig. 4B] was observed throughout the conditioning phase.

Mice treated with saline in home cage followed by 60 mg/kg of pregabalin treatment during the conditioning phase; we did not observe any significant effect over phase [F (1, 6) = 1, p = 0.3559], however we did observe a
significant effect between treatments [F (1, 6) = 7.605, p = 0.0330], and a significant interaction between phase and treatment [F (1, 6) = 39.63, p = 0.0007]. Post-hoc analysis demonstrated a significant increase in time spent in the pregabalin-paired chamber as compared to the saline-paired chamber in the post-test (p < 0.01; Fig. 5A) throughout the conditioning phase.

Treatment with 60 mg/kg of pregabalin after 30 minutes of treatment with 200 mg/kg of CEF, in home cages, resulted in no significant effect over phase [F (1, 8) = 1, p = 0.3466], between treatments [F (1, 8) = 0.07929, p = 0.7854], or between phase and treatment [F (1, 8) = 0.01454, p = 0.9070; Fig. 5B] throughout the conditioning phase.

Figure 2. Time spent in pregabalin-paired chamber as compared to saline-paired chamber in Preg-30 group (A). No significant changes in time spent were found in the tested chambers. Time spent in pregabalin-paired chamber as compared to saline-paired chamber in Preg-60 group (B). A significant increase in time spent was found in pregabalin-paired chamber as compared to saline-paired chamber during post-test. A significant increase in time spent was found in pregabalin-paired chamber during post-test as compared to pre-test. Values shown as means ± S.E.M. ****p < 0.0001 compared to saline-paired chamber. (**p < 0.01 compared to pre-test).

Figure 3. Time spent in pregabalin-paired chamber as compared to saline-paired chamber in Preg-90 group (A). A significant increase in time spent was found in pregabalin-paired chamber as compared to saline-paired chamber during post-test. Time spent in pregabalin-paired chamber as compared to saline-paired chamber in Preg-120 group (B). No significant changes in time spent were found in the tested chambers. Values shown as means ± S.E.M. *p < 0.05 compared to saline-paired chamber.
Discussion

In the present study, we demonstrate for the first time, using a mice model of drug addiction, that pregabalin can induce CPP. These findings are in contrast to previous reports, however, the maximum tested dose of pregabalin was 30 mg/kg, which did not induce rewarding effects and did not change place preference. Consistent with the previous findings from Andrews, et al., the dose of 30 mg/kg did not change place preference in our study. However, when the dose was increased to 60 mg/kg, a significant place preference was induced by pregabalin. This suggests a dose dependent effect of pregabalin's rewarding effects. Interestingly, this effect is supported by previous controlled clinical studies showing that pregabalin can cause euphoric effects as a side effect in participants of these studies.

The drug seeking effects found in several drugs of abuse have been consistently reported to be mediated by glutamatergic mechanism. GLT-1, an astrocyte-specific excitatory amino acid transporter, which is responsible for glutamate homeostasis in the brain. It had been previously demonstrated that downregulation of GLT-1
expression in the NAc was associated with continuous exposure to addicting drugs. Interestingly, GLT-1 expression was found to be downregulated instantly in cocaine self-administration model. Of note, the glutamatergic transmission is amplified as a result of increase in glutamate concentrations and decrease in glutamate uptake in the synapses. Additionally, it has been observed that glutamate receptors such as mGlu-5 and N-Methyl-D-aspartate could be potentiated and activated by the spillover of glutamate which enhances drug seeking behavior. In the present study, our results suggest that pregabalin at higher doses (60 mg, and 90 mg) may induce addiction partly by downregulating GLT-1 expression and thereby decreasing glutamate uptake at the synaptic cleft.

Treatment with CEF has been reported to prevent drug seeking behavior caused by, in part, decreased GLT-1 expression in methamphetamine, cocaine, ethanol, nicotine, and heroin dependence with the drug seeking associated with glutamate spillover secondary to GLT-1 downregulation. Additionally, the normalization of GLT-1 expression, by CEF treatment, was associated with a decrease in drug-seeking behavior. Therefore, pregabalin seeking at the addictive doses of (60 mg, and 90 mg) might be mediated by altering GLT-1 expression as the drug seeking effects of pregabalin was eliminated by CEF pretreatment in the present study. CEF has been demonstrated to have neuroprotective efficacy in many neurological disorders and can offer neuroprotective effects in drug addiction associated with glutamate excitotoxicity. CEF can freely pass the blood brain barrier and enter the central nervous system to up-regulate GLT-1 making it an attractive potential therapeutic for future clinical use in antagonizing pregabalin-induced drug-seeking behavior.

One limitation of the present study is that we did not demonstrate a mechanism of action for CEF in antagonism of pregabalin-induced drug-seeking behavior. GLT-1 plays a central role in inflammatory mechanisms in the brain, which has previously been demonstrated to be associated with drug addiction. It has been previously reported that central administration of some neurotoxins causes significant impairment in motor functions, increased neuroinflammation and increased drug addiction. Post-treatment with CEF (200 mg/ kg) significantly antagonized motor impairment, attenuated lipid peroxidation, restored endogenous antioxidant enzymes glutathione peroxide and catalase, and decreased drug addiction. Taken together, CEF-mediated antagonism of pregabalin-induced drug seeking like effects could promote restoration of glutamate homeostasis, and in this way modulate drug-seeking behavior. CEF could serve as a lead compound for developing treatment for pregabalin abuse as other pharmacological effects of this antibiotic could not be excluded.

Future studies are needed to investigate a mechanistic role for neuroinflammation in pregabalin abuse, as well as sex- and age-related mechanisms in pregabalin-induced neurochemical changes.

Received: 6 June 2019; Accepted: 30 September 2019;
Published online: 22 October 2019

References

1. UNODC, (Naciones Unidas Nueva York, 2013).
2. Bassiony, M. Substance use disorders in Saudi Arabia. Journal of Substance use 18, 450–466 (2013).
3. Saudigazette. Saudi youth and the abuse of prescription drugs, http://saudigazette.com.sa/article/155386/Saudi-youth-and-the-abuse-of-prescription-drugs (2016).
4. Halaby, A., Kassim, S. A. & Naja, W. J. Pregabalin dependence: a case report. Current drug safety 10, 184–186 (2015).
5. Aldemir, E., Akintoprak, A. E. & Cookunol, H. Pregabalin dependence: a case report. Turk Psikiyatri Derg 26, 217–220 (2015).
6. Bajmišlić, P., Ogić, G., Güven, F. M. & Batmaa, S. Pregabalin Dependence: A Case Report (2015).
7. Grosshans, M. et al. Pregabalin abuse, dependence, and withdrawal: a case report. American Journal of Psychiatry 167, 869–869 (2010).
8. Gahr, M., Franke, B., Friedemann, R. W., Kölle, M. A. & Schönfeldt-Lecuona, C. Concerns about pregabalin: further experience with its potential of causing addictive behaviors. Journal of addiction medicine 7, 147–149 (2013).
9. Filippetto, F. A., Zipp, C. P. & Coren, J. S. Potential for pregabalin abuse or diversion after past drug-seeking behavior. The Journal of the American Osteopathic Association 110, 605–607 (2010).
10. Chiappini, S. & Schifano, F. A F decade of gabapentinoid misuse: an analysis of the European Medicines Agency’s ‘Suspected Adverse Drug Reactions’ database. CNS drugs 30, 647–654 (2016).
11. Li, Z. et al. Pregabalin is a potent and selective ligand for α2β-1 and α2β-2 calcium channel subunits. European journal of pharmacology 667, 80–90 (2011).
12. Pepton, T., Moeller-Bertram, T., Schilling, J. M. & Wallace, M. S. Targeting voltage-gated calcium channels for the treatment of neuropathic pain: a review of drug development. Expert opinion on investigational drugs 20, 1277–1284 (2011).
13. Boschun, M. J. A meta-analysis of the efficacy of pregabalin in the treatment of generalized anxiety disorder. The Canadian Journal of Psychiatry 56, 558–566 (2011).
14. Feltner, D. E., Liu-Dumaw, M., Schweizer, E. & Bielski, R. Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study. International clinical psychopharmacology 26, 213–220 (2011).
15. Andrews, N. et al. Effect of gabapentin-like compounds on development and maintenance of morphine-induced conditioned place preference. Psychopharmacology 157, 381–387 (2001).
16. Rutten, K., Vry, J., Robena, A., Tschentke, T. M. & Kam, E. L. Dissociation of rewarding, anti-aversive and anti-nociceptive effects of different classes of anti-nociceptives in the rat. European Journal of Pain 15, 299–305 (2011).
17. Drug Enforcement Administration, D. o. J. Schedules of controlled substances: placement of pregabalin into schedule V. Final rule. Federal register 70, 43633 (2005).
18. Lang, N., Sueske, E., Hasan, A., Paulus, W. & Tergau, F. Pregabalin Exerts Oppositional Effects on Different Inhibitory Circuits in Human Motor Cortex: A Double-blind, Placebo-controlled Transcranial Magnetic Stimulation Study. Epilepsy 47, 813–819 (2006).
19. Chua, Y. et al. Randomised clinical trial: pregabalin attenuates the development of acid-induced oesophageal hypersensitivity in healthy volunteers–a placebo-controlled study. Alimentary pharmacology & therapeutics 35, 319–326 (2012).
20. Chew, M. L. et al. Pharmacokinetics of pregabalin controlled-release in healthy volunteers: effect of food in five single-dose, randomized, clinical pharmacology studies. Clinical drug investigation 34, 617–626 (2014).
21. Koob, G. F. & Bloom, F. E. Cellular and molecular mechanisms of drug dependence. Science 242, 715–723 (1988).
22. Bardos, M. T. Neuropharmacological mechanisms of drug reward: beyond dopamine in the nucleus accumbens. Critical Reviews in Neurobiology 12 (1998).
23. Wise, R. A. & Rompré, P. P. Brain dopamine and reward. Annual review of psychology 40, 191–225 (1989).
24. Fujio, M. et al. Gene transfer of GLT-1, a glutamate transporter, into the nucleus accumbens shell attenuates methamphetamine- and morphine-induced conditioned place preference in rats. European Journal of Neuroscience 22, 2744–2754 (2005).
25. Melendez, R. I., Hicks, M. P., Cagle, S. S. & Kalivas, P. W. Ethanol exposure decreases glutamate uptake in the nucleus accumbens. Alcoholism: Clinical and Experimental Research 29, 326–333 (2005).
26. Knackstedt, L. A., Melendez, R. I. & Kalivas, P. W. Ceftriaxone restores glutamate homeostasis and prevents relapse to cocaine seeking. Biological Psychiatry 67, 81–84 (2010).
27. Das, S. C., Yamamoto, B. K., Hristov, A. M. & Sari, Y. Ceftriaxone attenuates ethanol drinking and restores extracellular glutamate concentration normalization through normalization of GLT-1 in nucleus accumbens of male alcohol-prefering rats. Neuropharmacology (2015).
28. Althobaiti, Y. S., Alshehri, F. S., Almalki, A. H. & Sari, Y. Effects of ceftriaxone on glial glutamate transporters in Wistar rats administered sequential ethanol and methamphetamine. Frontiers in Neuroscience 10 (2016).
29. McFarland, K., Lapish, C. C. & Kalivas, P. W. Prefrontal glutamate release into the core of the nucleus accumbens mediates cocaine-induced reinstatement of drug-seeking behavior. The Journal of Neuroscience 23, 3531–3537 (2003).
30. McFarland, K., Davidve, S. B., Lapish, C. C. & Kalivas, P. W. Limbic and motor circuitry underlying footshock-induced reinstatement of cocaine-seeking behavior. The Journal of Neuroscience 24, 1551–1560 (2004).
31. Dravolina, O. A. et al. mGlu1 receptor blockade attenuates cue- and nicotine-induced reinstatement of extinguished nicotine self-administration behavior in rats. Neuropharmacology 52, 263–269 (2007).
32. Tessari, M., Pilla, M., Andreoli, M., Hutcheson, D. M. & Heidbreder, C. A. Antagonism at metabotropic glutamate 5 receptors inhibits nicotine-and cocaine-taking behaviours and prevents nicotine-triggered relapse to nicotine-seeking. European journal of pharmacology 499, 121–133 (2004).
33. Lee, B., Platt, D. M., Rowlett, J. K., Adewale, A. S. & Spealman, R. D. Attenuation of behavioral effects of cocaine by the metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethyl)-pyridine in squirrel monkeys: comparison with dizocilpine. Journal of Pharmacology and Experimental Therapeutics 312, 1232–1240 (2005).
34. Cornish, J. L. & Kalivas, P. W. Glutamate transmission in the nucleus accumbens mediates relapse in cocaine addiction. J Neurosci 20, RC89 (2000).
35. Park, W.-K. et al. Cocaine administered into the medial prefrontal cortex reinstates cocaine-seeking behavior by increasing AMPA receptor-mediated glutamate transmission in the nucleus accumbens. The Journal of Neuroscience 22, 2916–2925 (2002).
36. Bäckström, P. & Hyytiä, P. Involvement of AMPA/kainate, NMDA, and mGlu5 receptors in the nucleus accumbens core in cue-induced reinstatement of cocaine seeking in rats. Psychopharmacology 192, 571–580 (2007).
37. Danbolt, N. C. Glutamate uptake. Progress in neurobiology 65, 1–105 (2001).
38. Mitani, A. & Tanaka, K. Functional changes of glial glutamate transporter GLT-1 during ischemia: an in vivo study in the hippocampal CA1 of normal mice and mutant mice lacking GLT-1. The Journal of neuroscience 23, 7176–7182 (2003).
39. Alajaji, M., Bowers, M., Knackstedt, L. & Damaj, M. Effects of the beta-lactam antibiotic ceftriaxone on nicotine withdrawal and nicotine-induced reinstatement of preference in mice. Psychopharmacology 228, 419–426 (2013).
40. He, Z. et al. Inhibition of vesicular glutamate transporters contributes to attenuate methamphetamine-induced conditioned place preference in rats. Behavioural brain research 267, 1–5 (2014).
41. Althobaiti, Y. S., Alshehri, F. S., Almalki, A. H. & Sari, Y. Effects of ceftriaxone on glial glutamate transporters in Wistar rats administered sequential ethanol and methamphetamine. Frontiers in Neuroscience 10 (2016).
42. Qrunfleh, A. M., Alazizi, A. & Sari, Y. Ceftriaxone, a beta-lactam antibiotic, attenuates relapse-like ethanol-drinking behavior in alcohol-preferring rats. Alcoholism: Clinical and Experimental Research 32, 2288–2298, https://doi.org/10.1016/j.ber.2017.06.017 (2017).
43. Qrunfleh, A. M., Alazizi, A. & Sari, Y. Ceftriaxone, a beta-lactam antibiotic, attenuates relapse-like ethanol-drinking behavior in alcohol-preferring rats. Alcoholism: Clinical and Experimental Research 33, 1695–1700 (2009).
44. Trantham-Davidson, H., LaLumiere, R. T., Reissner, K. J., Kalivas, P. W. & Knackstedt, L. A. Ceftriaxone normalizes nucleus accumbens glutamate homeostasis and prevents relapse to methamphetamine-seeking in a condition place preference paradigm. Brain research 1456, 16–21 (2012).
45. Knackstedt, L. A., Melendez, R. I. & Kalivas, P. W. Ethanol exposure decreases glutamate uptake in the nucleus accumbens of male alcohol-prefering rats. Neuropharmacology 97, 67–74, https://doi.org/10.1016/j.neuropharm.2015.05.009 (2015).
46. Trantham-Davidson, H., Lalamure, R. T., Reissner, K. J., Kalivas, P. W. & Knackstedt, L. A. Ceftriaxone normalizes nucleus accumbens synaptic transmission, glutamate transport, and export following cocaine self-administration and extinction training. The Journal of neuroscience: the official journal of the Society for Neuroscience 32, 12406–12410, https://doi.org/10.1523/JNEUROSCI.1796-12.2012 (2012).
47. Shen, H.-W., Scofield, M. D., Boger, H., Hensley, M. & Kalivas, P. W. Synaptic glutamate spillover due to impaired glutamate uptake mediates heroin relapse. The Journal of neuroscience: the official journal of the Society for Neuroscience 34, 5649–5657, https://doi.org/10.1523/JNEUROSCI.4565-13.2014 (2014).
48. Knackstedt, L. A., Melendez, R. I. & Kalivas, P. W. Ceftriaxone restores glutamate homeostasis and prevents relapse to cocaine seeking. Biological psychiatry 67, 81–84, https://doi.org/10.1016/j.biopsych.2009.07.018 (2010).
Bisht, R., Kaur, B., Gupta, H. & Prakash, A. Ceftriaxone mediated rescue of nigral oxidative damage and motor deficits in MPTP

Chu, K.

Jones, D. C. & Miller, G. W. The effects of environmental neurotoxins on the dopaminergic system: a possible role in drug

Itzhak, Y., Martin, J. L., Black, M. D. & Ali, S. F. Effect of the dopaminergic neurotoxin MPTP on cocaine-induced locomotor

Reissner, K. J. et al. Glutamate transporter GLT-1 mediates N-acetylcysteine inhibition of cocaine reinstatement. Addiction biology

Rothstein, J. D. et al. β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature

Verma, R., Mishra, V., Sas mal, D. & Raghurir, R. Pharmacological evaluation of glutamate transporter 1 (GLT-1) mediated

Cui, C. et al. Neuroprotective effect of ceftriaxone in a rat model of traumatic brain injury. Neurological Sciences

Inui, T. et al. Neuroprotective effect of ceftriaxone on the penumbra in a rat venous ischemia model. Neuroscience

Leung, T. et al. Ceftriaxone ameliorates motor deficits and protects dopaminergic neurons in 6-hydroxydopamine-lesioned rats. ACS

chemical neuroscience

64. Leung, T.

65. Chen, S.-L. et al. Low-dose memantine attenuated morphine addictive behavior through its anti-inflammation and neurotrophic

effects in rats. Journal of Neuroimmune Pharmacology

66. Ward, R. J. et al. Neuro-inflammation induced in the hippocampus of ‘binge drinking’ rats may be mediated by elevated extracellular

glutamate content. Journal of neurochemistry

67. Eidson, L. N., Inoue, K., Young, L. J., Tansey, M. G. & Murphy, A. Z. Toll-like receptor 4 mediates morphine-induced

neuroinflammation and tolerance via soluble tumor necrosis factor signaling. Neuropsychopharmacology

68. Langston, J. W. Mechanism of MPTP toxicity: more answers, more questions. Trends in Pharmacological Sciences

69. Jones, D. C. & Miller, G. W. The effects of environmental neurotoxants on the dopaminergic system: a possible role in drug

addiction. Biochemical pharmacology

70. Izhak, Y., Martin, J. L., Black, M. D. & Ali, S. F. Effect of the dopaminergic neurotoxin MPTP on cocaine-induced locomotor

sensitization. Pharmacology Biochemistry and Behavior

71. Chu, K. et al. Pharmacological induction of ischemic tolerance by glutamate transporter-1 (EAAT2) upregulation. Stroke

72. Bish, R., Kaur, B., Gupta, H. & Prakash, A. Ceftriaxone mediated rescue of nigral oxidative damage and motor deficits in MPTP

model of Parkinson’s disease in rats. Neurotoxicology

Acknowledgements

The work was supported by Research group grant 1-439-6079 from Deanship of Scientific Research, Taif University, SA. The authors would like to thank Hussam Almalki for his help in the experiments and the graphic designer Marwah Alkhateeb for her help in the figures. Supported by American Heart Association Grant #14FTF-19970026 to CMS.

Author contributions

Y.S.A. conceptualized and designed the study, helped in the experiments, analyzed the data and wrote the first draft of the manuscript. A.A. and H.A. participated in the experiments, data analysis and helped in writing the manuscript. W.A., A.G., Q.A. and A.M.G.H. helped in analyzing data and editing the manuscript. A.N. and O.A. performed animal experiments. C.M.S. and Z.A.S. provided technical advice to overcome challenges in experiments and edited the manuscript. All authors approved the final version of the manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Correspondence and requests for materials should be addressed to Y.S.A.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019